CAR-TCR 2021: Specificity screening of CAR T cells

Our methodology for labelling and analysing whole CAR T cells is widely used for cross-reactivity screening of the finalised engineered CAR T cells. The Retrogenix technology is a standard IND-enabling safety assessment tool for developers of novel CAR T cell therapies.

Screen scFvs or whole CAR T cells

Retrogenix has two approaches for CAR T cell cross-reactivity screening:

  • Screen the antigen recognition element – the scFv / antibody
  • Screen whole engineered CAR T cells

Early specificity screening helps to de-risk programs and enable selection of the right scFv candidates in order to maximise the chances of producing the most promising CAR T therapy. This can be followed later by more thorough screening of the whole engineered T cell (or the final scFv) to provide a more in-depth assessment of off-target liability. As there may be a discordance between the off-target profile of the original antibody / scFv and the final engineered T cell it is possible to screen both to ensure that the binding profile has not been altered during development.

Find out more:

Your CAR-TCR contact

Nick Brown
Manager, Client Services
Retrogenix | A Charles River Company

Presenting at CAR TCR August 31st 2pm ET
‘Cell therapy specificity screening:
Assessing off-target liabilities and generating IND enabling data’

Email | LinkedIn | Telephone

Talk to us about a project

    I would like to thank you very much for the great and very timely work including this report which will be key data for our submission to the regulatory authorities.
    Marcel Walser, PhD, Senior Director Research, Molecular Partners
    Simcere logo
    Aveo Oncology - The Human Response
    Theraclone Sciences
    Bluebird Bio
    The Center for Infectious Disease Research
    Compugen Logo
    Sanofi Logo
    The University of Copenhagen
    Lund University
    NIH - National Institutes of Health
    The University of Pennsylvania
    Scripps Florida - The Scripps Research Institute
    Peptinnovate Ltd - Unlocking Nature's Potential
    The University of Sheffield
    Capella Bioscience Logo
    Unum Theraputics Logo
    Celyad Logo
    Genmab Logo
    Molecular Partners Logo
    NanoMab Logo